Siemens to distribute imaging agent
This article was originally published in The Gray Sheet
Executive Summary
In response to a Feb. 26 CMS coverage-with-evidence-development decision on the use of positron emission tomography in certain bone metastases treatments, Siemens Medical plans to distribute 18-F-sodium fluoride (NaF-18) through a network of 47 PET radiopharmacies in the U.S., the firm said March 5. The imaging agent is an alternative to Tc-99m, also used in PET scans, which has recently been in short supply (1"The Gray Sheet" March 1, 2010)
You may also be interested in...
Medicare In Brief
LVAD coverage analysis: CMS will consider whether to expand national Medicare coverage for ventricular assist device destination therapy to match recently updated FDA labeling for Thoratec's HeartMate II, the agency said Feb. 22. The coverage analysis was opened in response to a request by Thoratec, which gained PMA approval in January for its next-generation left-ventricular-assist device to keep alive end-stage heart failure patients who are not candidates for transplant (1"The Gray Sheet" Jan. 25, 2010). The FDA-indicated destination therapy population for HeartMate II includes a broader set of heart failure patients and a lower duration requirement for prior failed therapies than what was approved for Thoratec's older-generation HeartMate XVE, the device that formed the basis of the current Medicare destination therapy coverage policy established in 2003. CMS will issue a proposal by August 22 on whether to expand coverage and a final decision by Nov. 20. Comments are due March 24
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.